Ovarian Cancer

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Latest News

Shannon N. Westin, MD, MPH
Neoadjuvant Olaparib Proves Feasible, Aids Optimal Resection in BRCA-Mutant Ovarian Cancer

March 28th 2023

Neoadjuvant treatment with olaparib prior to surgical resection and adjuvant chemotherapy was well tolerated and led to a 100% optimal resection rate in patients with newly diagnosed, BRCA-mutant ovarian, primary peritoneal, or fallopian tube cancer.

Ursula Matulonis, MD
Niraparib Maintenance Does Not Produce Long-term OS Benefit in Recurrent Ovarian Cancer

March 27th 2023

Shannon N. Westin, MD, MPH, FACOG
Olaparib Plus Selumetinib Produces Clinical Benefit in RAS-Mutated Ovarian and Endometrial Cancer

March 27th 2023

Vadim Gushchin, MD
Long-Term HRQOL Remains Unimpaired With HIPEC Plus Cytoreductive Surgery in Newly Diagnosed Ovarian Cancer

March 26th 2023

Richard Murray, PhD
JTX-8064 Plus Pimivalimab Elicits Durable Responses in Platinum-Resistant Ovarian Cancer

March 17th 2023